Erythropoiesis and Erythropoietin in Multiple Myeloma

References

• Spivak J.L. Cancer-related anemia: Its causes and characteristics. Semin. Oncol. 1994; 21: 3–8, Suppl. 3
   PubMed Web of Science ®Google Scholar
• Means R.T., Jr., Krantz S.B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639–l641
   PubMed Web of Science ®Google Scholar
• Lee G.R. The anemia of chronic disease. Semin. Hematol 1983; 20: 61–80
   PubMed Web of Science ®Google Scholar
• Sears D. Anemia of chronic disease. Med. Clin. North Am. 1992; 76: 567–579
   PubMed Web of Science ®Google Scholar
• Fuchs D., Hausen A., Reibnegger G., Werner E.R., Werner-Felmayer G., Dierich M.P., Wachter H. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur. J. Haematol. 1991; 46: 65–70
   PubMed Web of Science ®Google Scholar
• Durie B.G., Salmon S.E. The current status and future prospects of treatment fix multiple myeloma. Clin. Haematol. 1982; 11: 181–210
   PubMedGoogle Scholar
• Rodriguez-Cimadevilla J.C., Beauchemin V., Villeneuve L., Letendre F., Shaw A., Hoang T. Coordinate secretion of interleukin-I beta and granulocyte-macrophage colony-stimulating factor by the blast cells of acute myeloblastic leukemia: role of interleukin-1 as an endogenous inducer. Blood 1990; 76: 1481–1489
   PubMed Web of Science ®Google Scholar
• Foa R., Massaia M., Cardona S., Tos A.G., Bianchi A., Attisano C., Guxini di A., Celle P.F., Fierro M.T. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990; 76: 393–400
   PubMed Web of Science ®Google Scholar
• Naumovski L., Utz P.J., Bergstrom S.K., Morgan R., Molina A., Toole J.J., Glader B.E., McFall P., Weiss L.M., Warnke R., Smith S.D. SUP-HDI: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma. Blood 1989; 74: 2733–2742
   PubMed Web of Science ®Google Scholar
• Kremer J.P., Reisbach G., Nerl C., Dormer P. B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor-beta. Br. J. Haematol. 1992; 80: 480–487
   PubMed Web of Science ®Google Scholar
• Emilie D., Coumbaras J., Raphael M., Devergne O., Delecluse H.J., Gisselbrecht C., Michiels J.F., van Damme J., Taga T., Kishimoto T., et al. Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients. Blood 1992; 80: 498–504
   PubMed Web of Science ®Google Scholar
• Balkwill F., Osbome R., Burke F., Naylor S., Talbot D., Durbin H., Tavernier J., Fiers W. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987; 2: 1229–1232
   PubMed Web of Science ®Google Scholar
• Hollen C.W., Henthom J., Koziol J.A., Burstein S.A. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br. J. Haematol. 1991; 79: 286–290
   PubMed Web of Science ®Google Scholar
• Tracey K.J., Wei H., Manogue K.R., Fong Y., Hesse D.G., Nguyen H.T., Kuo G.C., Beutler B., Cotran R.S., Cerami A., et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 1988; 167: 1211–1227
   PubMed Web of Science ®Google Scholar
• Moldawer L.L., Marano M.A., Wei H., Fong Y., Silen M.L., Kuo G., Manogue K.R., Vlassara H., Cohen H., Cerami A., et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J. 1989; 3: 1637–1643
   PubMed Web of Science ®Google Scholar
• Johnson R.A., Waddelow T.A., Caro J., Oliff A., Roodman G.D. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989; 74: 130–138
   PubMed Web of Science ®Google Scholar
• Blick M., Sherwin S.A., Rosenblum M., Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 1987; 47: 2986–2989
   PubMed Web of Science ®Google Scholar
• Roodman G.D., Bird A., Hutzler D., Montgomery W. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells. Exp. Hematol. 1987; 15: 928–935
   PubMed Web of Science ®Google Scholar
• Abboud S.L., Gerson S.L., Berger N.A. The effect of tumor necrosis factor on normal human hematopoietic progenitors. Cancer 1987; 60: 2965–2970
   PubMed Web of Science ®Google Scholar
• Means R.T., Jr., Dessypris E.N., Krantz S.B. Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells. J. Clin. Invest. 1990; 86: 538–541
   PubMed Web of Science ®Google Scholar
• Means R.T., Jr., Krantz S.B. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J. Clin. Invest. 1993; 91: 416–419
   PubMed Web of Science ®Google Scholar
• Johnson C.S., Keckler D.J., Topper M.I., Braunschweiger P.G., Furmanski P. In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678–683
   PubMed Web of Science ®Google Scholar
• Means R.T., Jr., Dessypris E.N., Krantz S.B. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J. Cell. Physiol. 1992; 150: 59–64
   PubMed Web of Science ®Google Scholar
• Wang C.Q., Udupa K.B., Lipschitz D.A. The role of macrophages in the regulation of erythroid colony growth in vitro. Blood 1992; 80: 1702–1709
   PubMed Web of Science ®Google Scholar
• Furmanski P., Johnson C.S. Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor. Blood 1990; 75: 2328–2334
   PubMed Web of Science ®Google Scholar
• Vadhan Raj S., Al Katib A., Bhalla R., Pelus L., Nathan C.F., Sherwin S.A., Oettgen H.F., Krown S.E. Phase I trial of recombinant interferon gamma in cancer patients. J. Clin. Oncol. 1986; 4: 137–146
   PubMed Web of Science ®Google Scholar
• Mamus S.W., Beck Schroeder S., Zanjani E.D. Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes. J. Clin. Invest. 1985; 75: 1496–1503
   PubMed Web of Science ®Google Scholar
• Raefsky E.L., Platanias L.C., Zoumbos N.C., Young N.S. Studies of interferon as a regulator of hematopoietic cell proliferation. J. Immunol. 1985; 135: 2507–2512
   PubMed Web of Science ®Google Scholar
• Ulich T.R., del Castillo J., Guo K.Z. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood 1989; 73: 108–110
   PubMed Web of Science ®Google Scholar
• Burstein S.A., Downs T., Friese P., Lynam S., Anderson S., Henthorn J., Epstein R.B., Savage K. Thrombocytopoiesis in normal and sublethally irradiated dogs: response to human interleukin-6. Blood 1992; 80: 420–428
   PubMed Web of Science ®Google Scholar
• Herodin F., Mestries J.C., Janodet D., Martin S., Mathieu J., Gascon M.P., Pemin M.O., Ythier A. Recombinant glycosylated human interleukin-6 accelerates peripheral blood platelet count recovery in radiation-induced bone marrow depression in baboons. Blood 1992; 80: 688–695
   PubMed Web of Science ®Google Scholar
• Weber J., Yang J.C., Topalian S.L., Parkinson D.R., Schwartzentruber D.S., Ettinghausen S.E., Gunn H., Mixon A., Kim H., Cole D., et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J. Clin. Oncol. 1993; 11: 499–506
   PubMed Web of Science ®Google Scholar
• Gardner J.D., Liechty K.W., Christensen R.D. Effects of interleukin-6 on fet al hematopoietic progenitors. Blood 1990; 75: 2150–2155
   PubMed Web of Science ®Google Scholar
• Chuncharunee S., Carter C.D., Studtmann K.E., Caro J., Coffey R.J., Dessypris E.N. Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumour necrosis factor in vivo. Br. J. Haematol. 1993; 84: 374–380
   PubMed Web of Science ®Google Scholar
• Miller K.L., Carlino J.A., Ogawa Y., Avis P.D., Carroll K.G. Alterations in erythropoiesis in TGF-beta I-treated mice. Exp. Hematol. 1992; 20: 951–956
   PubMed Web of Science ®Google Scholar
• Burdach S.E.G., Levitt L.J. Receptor-specific inhibition of bone marrow erythropoiesis by recombinant DNA-de-rived interleukin-2. Blood 1987; 69: 1368–1375
   PubMed Web of Science ®Google Scholar
• Ward H.P., Kurnick J.E., Pisarczyk M.J. Serum level of erythropoietin in anemias associated with chronic infection, malignancy, and primary hematopoietic disease. J. Clin. Invest. 1971; 50: 332–335
   PubMed Web of Science ®Google Scholar
• Dainiak N., Kulkarni V., Howard D., Kalmanti M., Dewey M.C., Hoffman R. Mechanisms of abnormal erythropoiesis in malignancy. Cancer 1983; 51: 1101–1106
   PubMed Web of Science ®Google Scholar
• Zucker S., Friedman S., Lysik R.M. Bone marrow erythropoiesis in the anemia of infection, inflammation, and malignancy. J. Clin. Invest. 1974; 53: 1132–1138
   PubMed Web of Science ®Google Scholar
• Schreuder W.O., Ting W.C., Smith S., Jacobs A. Testosterone, erythropoietin and anaemia in patients with disseminated bronchial cancer. Br. J. Haematol. 1984; 57: 521–526
   PubMed Web of Science ®Google Scholar
• Erslev A.J., Wilson J., Caro J. Erythropoietin titers in anemic, nonuremic patients. J. Lab. Clin. Med. 1987; 109: 429–433
   PubMed Web of Science ®Google Scholar
• Pohl C., Schobert I., Moter A., Woll E.M., Schwonzen M., Hiersche A., Diehl V. Serum erythropoietin levels in patients with Hodgkin's lymphoma at the time of diagnosis. Ann. Oncol. 1992; 3: 172–173
   PubMed Web of Science ®Google Scholar
• Jansen J.H., Wientjens G.J., Fibbe W.E., Ralph P., van Damme den J., Ottolander G.J., Willemze Kluin R., Nelemans J.C. Serum monocyte colony-stimulating factor, erythropoietin and interleukin-6 in relation to pancytopenia in hairy cell leukemia. Leukemia 1992; 6: 735–131
   PubMed Web of Science ®Google Scholar
• Barosi G., Liberato L.N., Guamone R. Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 1993; 83: 365–369
   PubMed Web of Science ®Google Scholar
• Bowen D.T., Jacobs A., Cotes P.M., Lewis T.C. Serum erythropoietin and erythropoiesis in patients with myelodysplastic syndromes. Eur. J. Haematol. 1990; 44: 30–32
   PubMed Web of Science ®Google Scholar
• Jacobs A., Janowska-Wieczorek A., Caro J., Bowen D.T., Lewis T. Circulating erythropoietin in patients with myelodysplastic syndromes. Br. J. Haematol. 1989; 73: 36–39
   PubMed Web of Science ®Google Scholar
• Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., Spivak J.L. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 1990; 322: 1689–1692
   PubMed Web of Science ®Google Scholar
• Matsumoto T., Endoh K., Kamisango K., Akamatsu K., Koizumi K., Higuchi M., Imai N., Mitsui H., Kawaguchi T. Effect of recombinant human erythropoietin on anticancer drug-induced anaemia. Br. J. Haematol. 1990; 75: 463–468
   PubMed Web of Science ®Google Scholar
• Smith D.H., Goldwasser E., Vokes E.E. Serum immunoerythropoietin levels in patients with cancer receiving (cisplatin-based chemotherapy. Cancer 1991; 68: 1101–1105
   PubMed Web of Science ®Google Scholar
• Bray G., Reaman G.H. Erythroporetin deficiency: a complication of cisplatin therapy and its treatment with recombinant human erythropoietin. Am. J. Pediatr. Hemutol. Oneol. 1991; 13: 426–430
   PubMedGoogle Scholar
• Hasegawa I., Tanaka K. Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecol. Oncol. 1992; 46: 65–68
   PubMed Web of Science ®Google Scholar
• Faquin W.C., Schneider T.J., Goldberg M.A. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987–1994
   PubMed Web of Science ®Google Scholar
• Fandrey J., Jelkmann W.E. Interleukin-l and tumor necrosis factor-alpha inhibit erythropoietin production in vitro. Ann. NY Acad. Sci. 1991; 628: 250–255
   PubMed Web of Science ®Google Scholar
• Jelkmann W., Pagel H., Wolff M., Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci. 1992; 50: 301–308
   PubMed Web of Science ®Google Scholar
• Means R.T., Jr., Krantz S.B. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991; 78: 2564–2567
   PubMed Web of Science ®Google Scholar
• Johnson C.S., Cook C.A., Furmanski P. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TIVF-alpha): reversal with exogenous erythropoietin (EPO). Exp. Hematol. 1990; 18: 109–113
   PubMed Web of Science ®Google Scholar
• Clibon U., Bonewald L., Caro J., Roodman G.D. Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo. Exp. Hematol. 1919; 18: 438–441
   Google Scholar
• Roeser H.P. Iron metabolism in inflammation and malignant disease. Iron in biochemistry and medicine II, M Jacobs, A. Worwood. Academic Press London. 1980; 605–640
   Google Scholar
• Letendre E.D. Iron metabolism during infection and neoplasia. Cancer Metastasis Rev. 1987; 6: 41–53
   PubMed Web of Science ®Google Scholar
• Cazzola M., Bergamaschi G., Dezza L., Arosio P. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood 1990; 75: 1903–1919
   PubMed Web of Science ®Google Scholar
• Haurani F.I., Green D., Young K. Iron absorption in hypoferremia. Am. J. Med. Sci. 1965; 249: 537–547
   PubMed Web of Science ®Google Scholar
• Haurani F.I., Young K., Tocantins L.M. Reutilization of iron in anemia complicating malignant neoplasms. Blood 1963; 22: 73–81
   PubMed Web of Science ®Google Scholar
• Fillet G., Beguin Y., Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74: 844–851
   PubMed Web of Science ®Google Scholar
• Douglas S.W., Adamson J.W. The anemia of chronic disorders. studies of marrow regulation and iron metabolism. Blood 1975; 45: 55–65
   PubMed Web of Science ®Google Scholar
• Klasing K.C. Effect of inflammatory agents and interleukin 1 on iron and zinc metabolism. Am J. Physiol. 1984; 247: R901–R904
   PubMed Web of Science ®Google Scholar
• Gordcuk V.R., Prithviraj P., Dolinar T., Brittenham G.M. Interleukin I administration in mice produces hypoferreinia despite neutropenia. J. Clin. Invest. 1988; 82: 1934–1938
   PubMed Web of Science ®Google Scholar
• Goldblum S.E., Cohen D.A., Jay M., McClain C.J. Interleukin I-induced depression of iron and zinc: role of granulocytes and lactoferrin. Am. J. Physiol. 1987; 252: E27–E32
   PubMed Web of Science ®Google Scholar
• Uchida T., Yamagiwa A., Nakamura K. The effect of interleukin-1 on iron metabolism in rats. Eur. J. Haematol. 1991; 46: 1–5
   PubMed Web of Science ®Google Scholar
• Alvarez-Hernandez X, Liceaga J., McKay I.C., Brock J.H. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab. Invest. 1989; 61: 319–322
   PubMed Web of Science ®Google Scholar
• Konijn A.M., Hershko C. Ferritin synthesis in inflammation I. Pathogenesis of impaired iron release. Br. J. Haematol. 1977; 37: 7–16
   PubMed Web of Science ®Google Scholar
• Rogers J.T., Bridges K.R., Durmowicz G.P., Glass J., Auron P.E., Munro H.N. Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J. Biol. Chem. 1990; 265: 14572–14578
   PubMed Web of Science ®Google Scholar
• Miller L.L., Miller S.C., Torti S.V., Tsuji Y., Torti F.M. Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc. Natl. Acad. Sci. USA 1991; 88: 4946–4950
   PubMed Web of Science ®Google Scholar
• Summers M.R., Jacobs A. Iron uptake and ferritin synthesis by peripheral blood leucocytes from normal subjects and patients with iron deficiency and the anemia of chronic disease. Br. J. Haematol. 1976; 34: 221–229
   PubMed Web of Science ®Google Scholar
• van Snick J.L., Masson P.I., Heremans J.F. The involvement of lactoferrin in the hyposideremia of acute inflammation. J. Exp. Med. 1974; 140: 1068–1084
   PubMed Web of Science ®Google Scholar
• Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma—new biological insights and advances in therapy. Blood 1989; 73: 865–879
   PubMed Web of Science ®Google Scholar
• Greipp P.R. Advances in the diagnosis and management of myeloma. Semin. Hematol. 1992; 29: 24–45
   PubMed Web of Science ®Google Scholar
• Klein B., Bataille K. Cytokine network inhuman multiple myeloma. Hematol. Oncol. Clin. North Am. 1992; 6: 273–284
   PubMed Web of Science ®Google Scholar
• Shimizu S., Yoshioka R., Hirose Y., Sugai S., Tachibana J., Konda S. Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines. J. Exp. Med. 1989; 169: 339–344
   PubMed Web of Science ®Google Scholar
• van Damme J., Opdenakker G., Simpson R.J., Rubira M.R., Cayphas S., Vink A, Billiau A., van Snick J. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytomas growth factor induced by interleukin 1 and tumor necrosis factor. J. Exp. Med. 1987; 165: 914–919
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–85
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Vink A., Coulie P., Wamier G., Renauld J.C., Stevens M., Donckers D., van Snick J. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J. Exp. Med. 1990; 172: 997–1000
   PubMed Web of Science ®Google Scholar
• Portier M., Zhang X.G., Ursule E., Lees D., Jourdan M., Bataille R., Klein B. Cytokine gene expression in human multiple myeloma. Br. J. Haematol. 1993; 85: 514–520
   PubMed Web of Science ®Google Scholar
• Cozzolino F, Torcia M., Aldinucci D., Rubartelli A., Miliani A., Shaw A.R., Lansdorp Di P.M., Guglielmo R. Production of inlerleukin-1 by bone marrow myeloma cells. Blood 1989; 74: 380–387
   PubMed Web of Science ®Google Scholar
• Kawano M., Yamamoto I., Iwato K., Tanaka H., Asaoku H., Tanabe O., Ishikawa H., Nobuyoshi M., Ohmoto Y., Hirai Y., Kuramoto A. Interleukin-l beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood. 1989; 73: 1646–1649
   PubMed Web of Science ®Google Scholar
• Lichtenstein A., Berenson J., Norman D., Chang M.P., Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989; 74: 1266–1273
   PubMed Web of Science ®Google Scholar
• Garrett I.R., Durie S.G., Nedwin G.E., Gillespie A., Bringman T., Sabatini M., Bertolini D.R., Mundy G.R. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N. Engl. J. Med. 1987; 317: 526–532
   PubMed Web of Science ®Google Scholar
• Yamamoto I., Kawano M., Sone T., Iwato K., Tanaka H., Ishikawa H., Kitamura N., Lee K., Shigeno C., Konishi J., et al. Production of interleukin 1 beta, a potent bone resorbing cytokine, by cultured human myeloma cells. Cancer Res. 1989; 49: 4242–4246
   PubMed Web of Science ®Google Scholar
• Bataille R., Klein B., Jourdan M., Rossi J.F., Durie B.G. Spontaneous secretion of tumor necrosis factor-beta by human myeloma cell lines. Cancer 1989; 63: 877–880
   PubMed Web of Science ®Google Scholar
• Cordingley F.T., Bianchi A., Hoffbrand A.V., Reittie J.E., Heslop H.E., Vyakarnam A., Turner M., Meager A., Brenner M.K. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1988; 1: 969–971
   PubMed Web of Science ®Google Scholar
• Carter A., Merchav Silvian S., Draxler I., Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br. J. Haematol. 1990; 74: 424–431
   PubMed Web of Science ®Google Scholar
• Kawano M., Tanaka H., Ishikawa H., Nobuyoshi M., Iwato K., Asaoku H., Tanabe O., Kuramoto A. Interleukin-I accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma. Blood 1989; 73: 2145–2148
   PubMed Web of Science ®Google Scholar
• Birgens Paaske H.S., Hansen O., Henriksen J.H., Wantzin P. Quantitation of erythropoiesis in myelomatosis. Scand, J. Haematol. 1979; 22: 357–363
   PubMedGoogle Scholar
• Cline M.J., Berlin N.I. Studies of the anemia of multiple myeloma. Am. J. Med. 1962; 33: 510–525
   PubMed Web of Science ®Google Scholar
• McGrath K.M., Stuart J.J., Richards F. Correlation between serum IgG. platelet membrane IgG, and platelet function in hypergammaglobulinaemic states. Br. J. Haematol. 1979; 42: 585–591
   PubMed Web of Science ®Google Scholar
• Kopp W.L., Mac Kinney A.A., Jr., Wasson G. Blood volume and hematocrit value in macroglobulinemia and myeloma. Arch. Intern. Med. 1969; 123: 394–397
   PubMed Web of Science ®Google Scholar
• Tuddenham E.G., Bradley J. Plasma volume expansion and increased serum viscosity in myeloma and macroglobulinaemia. Clin. Exp. Immunol. 1974; 16: 169–176
   PubMed Web of Science ®Google Scholar
• Bjorneboe Birger M., Jensen K. Plasma volume, colloid-osmotic pressure and gamma globulin in multiple myeloma. Acta Med. Scand. 1969; 186: 475–478
   PubMed Web of Science ®Google Scholar
• Paaske Hansen O., Drivsholm A. Interrelationships between blood volume, venous hematocrit and renal failure in myelomatosis. Scand, J. Haematol. 1978; 20: 461–466
   PubMedGoogle Scholar
• Huebers H.A., Beguin Y., Pootrakul P., Einspahr D., Finch C.A. Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990; 75: 102–107
   PubMed Web of Science ®Google Scholar
• Beguin Y., Yema M., Loo M., Weber M., Fillet G. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br. J. Haematol. 1992; 82: 648–653
   PubMed Web of Science ®Google Scholar
• Majumdar G., Westwood N.B., Bell-Witter C., Muggleston D., Phillips J., Pearson T.C. Serum erythropoietin and circulating BFU-E in patients with multiple myeloma and anaemia but without renal failure. Leuk. Lymphoma 1993; 9: 173–176
   PubMed Web of Science ®Google Scholar
• Nielsen O.J., Brandt M., Drivsholm A. The secretory erythropoietin response in patients with multiple myeloma and Waldenstrom's macroglobulinaemia. Scand, J. Clin. Luh. Invest. 1990; 50: 697–703
   PubMed Web of Science ®Google Scholar
• Paaske Hansen O., Thorling E.B., Drivsholm A. Serum erythropoietin in myelomatosis. Scand. J. Haematol. 1977; 19: 106–110
   PubMedGoogle Scholar
• Ariad S., Clifford D., Penfold G., Mac Phail A.P., Bezwoda W.R. Erythropoietin response in anaemic patients with multiple myeloma and other lymphoid malignancies infiltrating the bone marrow. Eur. J. Haematol. 1992; 49: 59–62
   PubMed Web of Science ®Google Scholar
• Singh A., Eckardt K.U., Zimmermann A., Gotz K.H., Hamann M., Ratcliffe P.J., Kurtz A., Reinhart W.H. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J. Clin. Invest. 1993; 91: 251–256
   PubMed Web of Science ®Google Scholar
• Beguin Y., Clemons G., Pootrakul P., Fillet G. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 1993; 81: 1067–1076
   PubMed Web of Science ®Google Scholar
• Aoki I., Nishijima K., Homori M., Nakahara K., Higashi K., Ishikawa K. Responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in multiple myeloma. Br. J. Haematol. 1992; 81: 463–469
   PubMed Web of Science ®Google Scholar
• Wu H.S., Little A.G. Perioperative blood transfusions and cancer recurrence. J. Clin. Oncol. 1988; 6: 1348–1354
   PubMed Web of Science ®Google Scholar
• Blajchman M.A., Bardossy L., Carmen R., Sastry A., Singal D.P. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993; 81: 1880–1882
   PubMed Web of Science ®Google Scholar
• Winearls C.G., Oliver D.O., Pippard M.J., Reid C., Downing M.R., Cotes P.M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175–1177
   PubMed Web of Science ®Google Scholar
• Eschbach J.W., Egrie J.C., Downing M.R., Browne J.K., Adamson J.W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N. Engl. J. Med. 1987; 316: 73–78
   PubMed Web of Science ®Google Scholar
• Taylor J., Mactier R.A., Stewart W.K., Henderson I.S. Effect of erythropoietin on anaemia in patients with myeloma receiving haemodialysis. Br. Med. J. 1990; 301: 476–477
   PubMed Web of Science ®Google Scholar
• Caillette A., Barreto S., Gimenez E., Labeeuw M., Zech P. Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis?. Clin. Nephrol. 1993; 40: 176178
   Google Scholar
• Van der Niepen P., Sennesael J., Verbeelen D. r-HuEPO treatment of anemia associated with multiple myeloma and ESRD [letter]. Clin. Nephrol. 1993; 39: 113
   PubMed Web of Science ®Google Scholar
• Bergsagel D.E., Fitzgerald B., Quirt I. Treatment of anemia associated with multiple myeloma [letter]. N. Engl. J. Med. 1991; 324: 59–60
   PubMed Web of Science ®Google Scholar
• Ludwig H., Fritz E., Kotzmann H., Hockner P., Gisslinger H., Barnas U. Treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 1991; 325: 62–63
   PubMedGoogle Scholar
• Greenspan E. Treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 1991; 325: 62
   PubMedGoogle Scholar
• Bergsagel D.E., Fitzgerald B., Meharchand J., Hasselback R. Treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 1991; 325: 62
   PubMedGoogle Scholar
• Ludwig H., Fritz E., Kotzmann H., Hocker P., Gisslinger H., Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 1990; 322: 1693–1699
   PubMed Web of Science ®Google Scholar
• Rogers S., Russell N.H., Morgan A.G. Effect of erythropoietin in patients with myeloma [letter]. Br. Med. J. 1990; 301: 667
   PubMed Web of Science ®Google Scholar
• Kimata H., Yoshida A., Ishioka C., Mikawa H. Erythropoietin enhances immunoglobulin production and proliferation by human plasma cells in a serum-free medium. Clin. Immunol. Immunopathol. 1991; 59: 495–501
   PubMedGoogle Scholar
• Ludwig H., Fritz E., Leitgeb C., Krainer M., Kuhrer I., Sagaster P., Umek H. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann. Oncol. 1993; 4: 161–167
   PubMed Web of Science ®Google Scholar
• Ludwig H., Pecherstorfer M., Leitgeb C., Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells 1993; 11: 348–355
   PubMed Web of Science ®Google Scholar
• Barlogie B., Beck T. Recombinant human erythropoietin and the anemia of multiple myeloma. Stem Cells 1993; 11: 88–94
   PubMed Web of Science ®Google Scholar
• Oster W., Herrmann F., Gamm H., Zeile G., Lindemann A., Muller G., Brune T., Kraemer H.P., Mertelsmann R. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J. Clin. Oncol. 1990; 8: 956–962
   PubMed Web of Science ®Google Scholar
• Platanias L.C., Miller C.B., Mick R., Hart R.D., Ozer H., McEvilly J.M., Jones R.J., Ratain M.J. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J. Clin. Oncol. 1991; 9: 2021–2026
   PubMed Web of Science ®Google Scholar
• Shimamoto Y., Matsuzaki M., Yamaguchi M. Effective treatment of the anaemia associated with multiple myeloma by recombinant human erythropoietin. Clin. Lab. Haematol. 1991; 13: 311–313
   PubMedGoogle Scholar
• Case D.C., Jr., Bukowski R.M., Carey R.W., Fishkin E.H., Henry D.H., Jacobson R.J., Jones S.E., Keller A.M., Kugler J.W., Nichols C.R., et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J. Natl. Cancer Inst. 1993; 85: 801–806
   PubMed Web of Science ®Google Scholar
• Cazzola M., Ponchio L., Beguin Y., Rosti V., Bergamaschi G., Liberato N.L., Fregoni V., Nalli G., Barosi G., Ascari E. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992; 79: 29–37
   PubMed Web of Science ®Google Scholar
• Abels R.I. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol. 1992; 87: 4–11, Suppl l
   PubMed Web of Science ®Google Scholar
• Abels R.I. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin. Oncol. 1992; 19: 29–35
   PubMed Web of Science ®Google Scholar
• Henry D.H., Abels R.I. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies. Semin. Hematol. 1994; 21: 21–28, Suppl. 3
   Google Scholar
• Beguin Y., Loo M., R'Zik S., Sautois B., Le Jeune F., Rorive G., Fillet G. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 1993; 82: 2010–2016
   PubMed Web of Science ®Google Scholar